{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04691817",
            "orgStudyIdInfo": {
                "id": "UPCC 16520"
            },
            "organization": {
                "fullName": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy",
            "officialTitle": "A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "tocilizumab-and-atezolizumab-in-adults-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-refractory-to-line-immune-checkpoint-inhibitor-based-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-08",
            "studyFirstSubmitQcDate": "2020-12-30",
            "studyFirstPostDateStruct": {
                "date": "2020-12-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Genentech, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Lung Cancer, Nonsmall Cell"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 28,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Atezolizumab and Tocilizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days",
                    "interventionNames": [
                        "Drug: Atezolizumab",
                        "Drug: Tocilizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Atezolizumab",
                    "description": "1200mg infusion",
                    "armGroupLabels": [
                        "Atezolizumab and Tocilizumab"
                    ],
                    "otherNames": [
                        "Tecentriq"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tocilizumab",
                    "description": "Tocilizumab 6mg/kg or 4mg/kg infusion",
                    "armGroupLabels": [
                        "Atezolizumab and Tocilizumab"
                    ],
                    "otherNames": [
                        "Actemra, RoActemra, RO4877533"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Assess the proportion of patients with a radiologic response by RECIST 1.1 at 12 weeks.",
                    "timeFrame": "From first dose of protocol treatment until radiologic disease assessment at 12 weeks."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall survival (OS)",
                    "description": "Estimate the time from first dose of protocol treatment until death due to any cause or last patient contact alive until 3 months after study closure",
                    "timeFrame": "From first dose of protocol treatment until death due to any cause or last patient contact alive until 3 months after study closure."
                },
                {
                    "measure": "Dose Limiting Toxicities of the combination",
                    "description": "Determine dose limiting toxicities of the combination",
                    "timeFrame": "From first dose of protocol treatment until 49 days post treatment"
                },
                {
                    "measure": "Progression free survival (PFS).",
                    "description": "Estimate the time from first dose of protocol treatment until first radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if there is no progression date registered.",
                    "timeFrame": "From 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months."
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Clinical outcomes",
                    "description": "Correlate clinical outcomes with potential markers of immune escape and changes in the tumor microenvironment and blood using a novel field theory based methods under development by Cold Spring Harbor Laboratory.",
                    "timeFrame": "From enrollment until dealth due to any cause or last patient contact alive until 3 months after study closure"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Melissa Volpe, BA",
                    "role": "CONTACT",
                    "phone": "215-220-9703",
                    "email": "melissa.volpe@pennmedicine.upenn.edu"
                },
                {
                    "name": "Melina Marmarelis, MD, MSCE",
                    "role": "CONTACT",
                    "phone": "215-615-5835",
                    "email": "melina.marmarelis@pennmedicine.upenn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Melina Marmarelis, MD, MSCE",
                    "affiliation": "Abramson Cancer Center at Penn Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Abramson Cancer Center of the University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mel V, BA",
                            "role": "CONTACT",
                            "phone": "215-220-9703",
                            "email": "Melissa.volpe@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "Melina Marmarelis, MD, MSCE",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Lung Cancer, Nonsmall Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000594389",
                    "term": "Atezolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M349417",
                    "name": "Atezolizumab",
                    "asFound": "Status",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}